AP2008004470A0 - Spirocyclic quinazoline derivatives as pde7 inhibitors - Google Patents

Spirocyclic quinazoline derivatives as pde7 inhibitors

Info

Publication number
AP2008004470A0
AP2008004470A0 AP2008004470A AP2008004470A AP2008004470A0 AP 2008004470 A0 AP2008004470 A0 AP 2008004470A0 AP 2008004470 A AP2008004470 A AP 2008004470A AP 2008004470 A AP2008004470 A AP 2008004470A AP 2008004470 A0 AP2008004470 A0 AP 2008004470A0
Authority
AP
ARIPO
Prior art keywords
spirocyclic
quinazoline derivatives
pde7 inhibitors
pde7
inhibitors
Prior art date
Application number
AP2008004470A
Other languages
English (en)
Inventor
David James Rawson
Nigel Alan Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AP2008004470A0 publication Critical patent/AP2008004470A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2008004470A 2005-12-02 2006-11-23 Spirocyclic quinazoline derivatives as pde7 inhibitors AP2008004470A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10
PCT/IB2006/003388 WO2007063391A2 (en) 2005-12-02 2006-11-23 Spirocyclic quinazoline derivatives as pde7 inhibitors

Publications (1)

Publication Number Publication Date
AP2008004470A0 true AP2008004470A0 (en) 2008-06-30

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004470A AP2008004470A0 (en) 2005-12-02 2006-11-23 Spirocyclic quinazoline derivatives as pde7 inhibitors

Country Status (22)

Country Link
US (1) US7507742B2 (sr)
EP (1) EP1957467A2 (sr)
JP (1) JP2009517453A (sr)
KR (1) KR101009554B1 (sr)
AP (1) AP2008004470A0 (sr)
AR (1) AR058266A1 (sr)
AU (1) AU2006321349A1 (sr)
BR (1) BRPI0619126A2 (sr)
CA (1) CA2631535C (sr)
CR (1) CR10039A (sr)
EA (1) EA200801145A1 (sr)
EC (1) ECSP088484A (sr)
GT (1) GT200600494A (sr)
MA (1) MA30014B1 (sr)
ME (1) MEP0408A (sr)
NL (1) NL2000336C2 (sr)
NO (1) NO20082077L (sr)
PE (1) PE20071087A1 (sr)
RS (1) RS20080233A (sr)
TW (1) TW200732307A (sr)
UY (1) UY29979A1 (sr)
WO (1) WO2007063391A2 (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
JP5580192B2 (ja) * 2007-03-27 2014-08-27 オメロス コーポレーション 運動障害の処置のためのｐｄｅ７インヒビターの使用
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100216823A1 (en) * 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
CN106038567A (zh) 2010-11-08 2016-10-26 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2019014305A1 (en) * 2017-07-12 2019-01-17 Dart Neuroscience, Llc SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS
US20260048059A1 (en) 2022-08-18 2026-02-19 Klaus Wirth Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083772A1 (en) 2000-04-28 2001-11-08 Merck Patent Gmbh Splice variant of camp phosphodiesterase type 7 (pde7a3)
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2599662A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain

Also Published As

Publication number Publication date
US20070129388A1 (en) 2007-06-07
RS20080233A (sr) 2009-07-15
KR20080059338A (ko) 2008-06-26
EP1957467A2 (en) 2008-08-20
AR058266A1 (es) 2008-01-30
BRPI0619126A2 (pt) 2011-09-13
WO2007063391A2 (en) 2007-06-07
CA2631535A1 (en) 2007-06-07
PE20071087A1 (es) 2007-12-29
CR10039A (es) 2008-07-10
TW200732307A (en) 2007-09-01
NO20082077L (no) 2008-06-04
NL2000336A1 (nl) 2007-06-05
GT200600494A (es) 2007-07-06
EA200801145A1 (ru) 2008-10-30
ECSP088484A (es) 2008-06-30
MEP0408A (xx) 2010-02-10
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (en) 2007-09-13
CA2631535C (en) 2010-07-27
MA30014B1 (fr) 2008-12-01
JP2009517453A (ja) 2009-04-30
AU2006321349A1 (en) 2007-06-07
US7507742B2 (en) 2009-03-24
NL2000336C2 (nl) 2007-08-07
UY29979A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200710951B (en) Piperidinyl-substituted isoquinolone derivatives as Rhokinase inhibitors
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ZA200702877B (en) Quinazoline derivatives
EG25942A (en) Quinazolinedione derivatives as parp inhibitors
PL2044056T3 (pl) Pochodne pirymidyny jako inhibitory ALK-5
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
SI2078001T1 (sl) Derivati diazepan-acetamida kot selektivni zaviralci 11 -hsd1
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA200903175B (en) Spiro-piperidine derivatives
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
IL187575A0 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
AP2008004470A0 (en) Spirocyclic quinazoline derivatives as pde7 inhibitors
IL198346A0 (en) Macrocyclic quinazoline derivatives as vegfr3 inhibitors
GB0504018D0 (en) Quinazoline derivatives
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
GB0506657D0 (en) Quinazoline derivatives
GB0524001D0 (en) Quinazoline derivatives
GB0501614D0 (en) Quinazoline derivatives